Robert T Greenlee, Alan S Go, Pamela N Peterson, Andrea E Cassidy-Bushrow, Charles Gaber, Romel Garcia-Montilla, Karen A Glenn, Nigel Gupta, Jerry H Gurwitz, Stephen C Hammill, John J Hayes, Alan Kadish, David J Magid, David D McManus, Deborah Multerer, J David Powers, Liza M Reifler, Kristi Reynolds, Claudio Schuger, Param P Sharma, David H Smith, Mary Suits, Sue Hee Sung, Paul D Varosy, Humberto J Vidaillet, Frederick A Masoudi
BACKGROUND: Primary prevention implantable cardioverter-defibrillators (ICDs) reduce mortality in selected patients with left ventricular systolic dysfunction by delivering therapies (antitachycardia pacing or shocks) to terminate potentially lethal arrhythmias; inappropriate therapies also occur. We assessed device therapies among adults receiving primary prevention ICDs in 7 healthcare systems. METHODS AND RESULTS: We linked medical record data, adjudicated device therapies, and the National Cardiovascular Data Registry ICD Registry...
March 26, 2018: Journal of the American Heart Association